Neimeth International Pharmaceutical Plc has posted a staggering 211 per cent growth in net profit. This is contained in its unaudited report for the fourth quarter ending December 31, 2025 submitted to the Nigerian Exchange Limited (NGX). The report shows a strong recovery from a loss of N885.33 million in 2024 to a profit of N982.11 million at full-year ending December 31, 2025.
Operating profit surged significantly from N18.886 million to N2.7 billion, a 14,257per cent jump.
Profit before taxation grew by 274 per cent from a loss of N854.546 million in 2024 to N1.48 billion in 2025 business year.
Sales revenue rose significantly by 64 per cent to N7.37 billion from N4.49 billion in 2024. Despite the significant increase in sales revenue the company managed cost of sales so well thus recording N4.0 billion on a total sales revenue of N7.34 billion against N2.5 billion for sales of N4.49 billion.
Marketing and distribution expenses inched up by 11 per cent despite inflationary pressures in the larger economy. The company reined in costs through prudent measures. Administrative costs were reduced by 88 per cent. Finance costs only rose by 40 per cent from N873,320 million to N1.22 billion. Having renegotiated its foreign exchange denominated facilities in the course of the year the company made a foreign exchange gain of N48 million in 2025 against a loss of over N2 billion in 2024. Following its business performance in 2025 Neimeth’s Earnings Per Share (EPS), recorded 22.98 kobo, up from a loss per share of 20.72 kobo in 2024. The stock saw a major rebound in 2025, gaining over 45 per cent following improved performance and strategic plans.
The Stock Market has reacted positively to the indices of performance of the company. With a market capitalization of N45.72 billion the stock of Neimeth has shown significant growth from N5.80 at the beginning of trading this year, to N9.80 as at close of trading on January 30, 2026, a 69 per cent appreciation.
Explaining the excellent growth trajectory of the company, Managing Director /CEO of Neimeth, Mr. Valentine Okelu said strategic planning, prudent spending and cost effective and efficient route to market combined to earn Neimeth the results.
He assured shareholders and numerous stakeholders of Neimeth that better days are here. “We aim to double our earnings and profitability”, he said.
“We aim to capture the continental market and we shall work to achieve that goal.”
Okelu said the allure of Neimeth does not lie in its rich history of pharmaceutical production in Nigeria, rather Neimeth’s strategic plans for the future holds the key as a continental leader for the industry.
Neimeth recently concluded a facility upgrade that raised its production capacity by 300 per cent. The company is also undertaking an expansion programme involving the construction of a world class World Health Organisation (WHO) standard pharmaceutical manufacturing facility at Amawbia in Anambra state. When completed the facility will produce a sizeable part of Africa’s medicine needs and will serve as a centre of excellence for pharmaceutical production in the continent.